01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference
November 24, 2021 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 03, 2021 07:00 ET | Praxis Precision Medicines, Inc.
Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies in post-traumatic...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
October 22, 2021 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference
September 01, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
July 06, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
May 14, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 11, 2021 08:00 ET | Praxis Precision Medicines, Inc.
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
April 30, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
April 29, 2021 08:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
April 14, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...